Roche Holding AG (SW:ROP) — Market Cap & Net Worth

$278.72 Billion USD  · CHF220.46 Billion CHF  · Rank #64

Market Cap & Net Worth: Roche Holding AG (ROP)

Roche Holding AG (SW:ROP) has a market capitalization of $278.72 Billion (CHF220.46 Billion) as of April 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #64 globally and #1 in its home market, demonstrating a 1.04% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Roche Holding AG's stock price CHF320.00 by its total outstanding shares 688926637 (688.93 Million).

Roche Holding AG Market Cap History: 2026 to 2026

Roche Holding AG's market capitalization history from 2026 to 2026. Data shows growth from $278.72 Billion to $278.72 Billion (0.00% CAGR).

Roche Holding AG Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Roche Holding AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of ROP by Market Capitalization

Companies near Roche Holding AG in the global market cap rankings as of April 18, 2026.

Key companies related to Roche Holding AG by market ranking:

  • Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $829.71 Billion USD.
  • Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $564.21 Billion USD.
  • Novartis AG (SW:NOVN): Ranked #69 globally with a market cap of $241.30 Billion USD ( CHF190.86 Billion CHF).
  • AbbVie Inc (NYSE:ABBV): Ranked #33 globally with a market cap of $368.45 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#16 Eli Lilly and Company NYSE:LLY $829.71 Billion $927.03
#19 Johnson & Johnson NYSE:JNJ $564.21 Billion $234.18
#69 Novartis AG SW:NOVN $241.30 Billion CHF118.26
#33 AbbVie Inc NYSE:ABBV $368.45 Billion $208.38

Roche Holding AG Historical Marketcap From 2026 to 2026

Between 2026 and today, Roche Holding AG's market cap moved from $278.72 Billion to $ 278.72 Billion, with a yearly change of 0.00%.

Year Market Cap Change (%)
2026 CHF278.72 Billion --

End of Day Market Cap According to Different Sources

On Apr 18th, 2026 the market cap of Roche Holding AG was reported to be:

Source Market Cap
Yahoo Finance $278.72 Billion USD
MoneyControl $278.72 Billion USD
MarketWatch $278.72 Billion USD
marketcap.company $278.72 Billion USD
Reuters $278.72 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Roche Holding AG

SW:ROP Switzerland Drug Manufacturers - General
Market Cap
$278.72 Billion
CHF220.46 Billion CHF
Market Cap Rank
#64 Global
#1 in Switzerland
Share Price
CHF320.00
Change (1 day)
+2.07%
52-Week Range
CHF300.90 - CHF323.90
All Time High
CHF323.90
About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more